TradingViewTradingView

Ginkgo Bioworks Holdings, Inc. SEC 10-Q Report

Bacaan 2 minit

Ginkgo Bioworks Holdings, Inc., a leading synthetic biology company, has released its Form 10-Q report for the second quarter of 2025. The report highlights the company's financial performance and operational achievements, showcasing its efforts in cell engineering and biosecurity. The company has demonstrated growth in revenue and a significant reduction in net loss, driven by strategic cost management and restructuring efforts.

Financial Highlights

  • Total Revenue: $97.9 million, reflecting a slight increase from $94.2 million in the same period last year, driven by growth in Cell Engineering revenue.
  • Loss from Operations: $(154.5) million, indicating a reduction in operating loss compared to $(400.9) million in the prior year, primarily due to cost management and restructuring efforts.
  • Net Loss: $(151.3) million, an improvement from $(383.1) million in the previous year, attributed to reduced operating expenses and restructuring charges.
  • Basic Net Loss Per Share: $(2.77), compared to $(7.55) in the prior year, reflecting the impact of reduced net loss and an increase in weighted average shares outstanding.
  • Diluted Net Loss Per Share: $(2.77), compared to $(7.56) in the prior year, consistent with the basic net loss per share due to anti-dilutive effects.

Business Highlights

  • Revenue Segments: The company operates in two main segments: Cell Engineering and Biosecurity. Cell Engineering revenue is generated through end-to-end cell engineering solutions and tools offerings, while Biosecurity revenue comes from biomonitoring and bioinformatics support services.
  • Cell Engineering Segment: This segment includes services for biological R&D, with revenue generated from service fees and downstream value share in the form of milestone payments, royalties, or equity interests. The company has expanded its offerings to include cell engineering tools, such as Datapoints and lab automation solutions.
  • Biosecurity Segment: The Biosecurity business focuses on building a global immune system to identify, monitor, prevent, and mitigate biological threats. The primary offerings are Canopy, which provides biomonitoring programs, and Horizon, a digital surveillance platform.
  • Geographical Performance: The majority of the company's revenue is generated from customers located in the United States, accounting for 75% of total revenue for the three months ended June 30, 2025.
  • New Product Launches: In the third quarter of 2024, the company launched new cell engineering tools offerings, including Datapoints for data generation and lab automation solutions.
  • Future Outlook: The company is focused on enhancing its platform capabilities and expanding its service offerings. It aims to continue improving its Foundry and Codebase to support more successful biological R&D and to build a robust early warning system for biological threats through its Biosecurity segment.

SEC Filing: Ginkgo Bioworks Holdings, Inc. [ DNA ] - 10-Q - Aug. 07, 2025